M
Marc Ferrante
Researcher at Katholieke Universiteit Leuven
Publications - 557
Citations - 21117
Marc Ferrante is an academic researcher from Katholieke Universiteit Leuven. The author has contributed to research in topics: Medicine & Ulcerative colitis. The author has an hindex of 56, co-authored 401 publications receiving 16393 citations. Previous affiliations of Marc Ferrante include Catholic University of Leuven & University Medical Center Utrecht.
Papers
More filters
Journal ArticleDOI
Long-term expansion of epithelial organoids from human colon, adenoma, adenocarcinoma, and Barrett's epithelium.
Toshiro Sato,Daniel E. Stange,Marc Ferrante,Marc Ferrante,Robert G.J. Vries,Johan H. van Es,Stieneke van den Brink,Winan J. van Houdt,Apollo Pronk,Joost van Gorp,Peter D. Siersema,Hans Clevers +11 more
TL;DR: A technology that can be used to study infected, inflammatory, or neoplastic tissues from the human gastrointestinal tract is developed that might have applications in regenerative biology through ex vivo expansion of the intestinal epithelia.
Journal ArticleDOI
A decrease of the butyrate-producing species Roseburia hominis and Faecalibacterium prausnitzii defines dysbiosis in patients with ulcerative colitis
Kathleen Machiels,Marie Joossens,João Sabino,Vicky De Preter,Ingrid Arijs,Venessa Eeckhaut,Vera Ballet,Karolien Claes,Filip Van Immerseel,Kristin Verbeke,Marc Ferrante,Jan Verhaegen,Paul Rutgeerts,Severine Vermeire +13 more
TL;DR: The composition of the fecal microbiota of UC patients differs from that of healthy individuals: the authors found a reduction in R hominis and F prausnitzii, both well-known butyrate-producing bacteria of the Firmicutes phylum, suggesting that different bacterial species contribute to the pathogenesis of UC and CD.
Journal ArticleDOI
Expanded allogeneic adipose-derived mesenchymal stem cells (Cx601) for complex perianal fistulas in Crohn's disease: a phase 3 randomised, double-blind controlled trial.
Julián Panés,Damián García-Olmo,Gert Van Assche,Jean-Frederic Colombel,Walter Reinisch,Walter Reinisch,Daniel C. Baumgart,Axel Dignass,Maria Nachury,Marc Ferrante,Lili Kazemi-Shirazi,Jean Charles Grimaud,Fernando de la Portilla,Eran Goldin,Marie Paule Richard,Anne Leselbaum,Silvio Danese +16 more
TL;DR: Cx601 is an effective and safe treatment for complex perianal fistulas in patients with Crohn's disease who did not respond to conventional or biological treatments, or both.
Journal ArticleDOI
Trough Concentrations of Infliximab Guide Dosing for Patients With Inflammatory Bowel Disease
Niels Vande Casteele,Marc Ferrante,Gert Van Assche,Vera Ballet,Griet Compernolle,Kristel Van Steen,Steven Simoens,Paul Rutgeerts,Ann Gils,Severine Vermeire +9 more
TL;DR: After dose optimization, continued concentration-based dosing of infliximab was not superior to clinically based dosing for achieving remission after 1 year, but was associated with fewer flares during the course of treatment.
Journal ArticleDOI
Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease
Geert R. D'Haens,Marc Ferrante,Severine Vermeire,Filip Baert,Maja Noman,Liesbeth Moortgat,P. Geens,Doreen Iwens,Isolde Aerden,Gert Van Assche,Gust Van Olmen,Paul Rutgeerts +11 more
TL;DR: Fecal calprotectin levels correlate significantly with endoscopic disease activity in IBD and appears useful in clinical practice for assessment of endoscopic activity and remission.